All In Biotech

NDA 205582 · Sun Pharm

Decitabine

Decitabine · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Sep 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jan 23, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

538

69 Phase 3, 82 recruiting

FAERS reports

4,367

4,145 serious, 1,166 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 23, 2020.

Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for Injection is a nucleoside metabolic inhibitor indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate­-2, and high-risk International Prognostic Scoring System groups. (1)

Mechanism: Decitabine is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DECITABINE · DECITABINE 50MG/VIAL · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Decitabine" as an intervention, any sponsor and status, largest first.

All 538 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use508
  • febrile neutropenia456
  • myelosuppression438
  • drug ineffective349
  • neutropenia334
  • pneumonia325
  • thrombocytopenia291
  • death287
  • pyrexia263
  • acute myeloid leukaemia242
  • anaemia218
  • product use in unapproved indication218

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20061
20077
200811
200943
201029
2011123
2012132
201386
201475
201575
2016103
2017172
2018249
2019322
2020491
2021451
2022517
2023452
2024367
2025343
2026317

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Decitabine (Decitabine)

2024 spending

$361K

Beneficiaries

59

305 claims

Per beneficiary

$6,117

$281.57 per unit

View as table
YearSpending
2020$586,669
2021$739,607
2022$771,638
2023$570,000
2024$360,887

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 337 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.